Ruckus Wireless Inc (NYSE:RKUS) up by 4.89%, Amarin Corporation plc (NASDAQ:AMRN)

Posted by Michael Korte May 17, 2013 0 Comment 1012 views


Ruckus Wireless Inc (NYSE:RKUS): In Thursday’s trading session, Ruckus Wireless Inc (NYSE:RKUS) gained 4.89%. Its opening price of $12.75 rose to touch an intraday high of $13.73 which eventually headed down to close at $13.30 per share. Over 2.46 million shares exchanged hands in the previous trading session. This number stood above the average volume of 0.725 million that was measured over a 30-day period.

Ruckus Wireless Inc posted a Q1 net income of $0.3 million or a breakeven per share from $3.7 million or $0.03 per share that it stood at, last year. The adjusted net income dropped from from the $5.0 million or $0.07 per share that it stood at, last year to $2.9 million or $0.03 per share. On an average, for the quarter, analysts had projected EPS of $0.04 on revenues of 63.27 million. In the first-quarter, there was a 27 percent rise in revenues which grew from $45.0 million last year to $57.2 million There was a $38.6 million in total operating costs in comparison to the $23.9 million last year.

Amarin Corporation plc (NASDAQ:AMRN): In Thursday’s trading session, Amarin Corporation plc (NASDAQ:AMRN) dropped 0.82%. Its opening price of $7.39 rose to touch an intraday high of $7.46 which eventually headed down to close at $7.23 per share. Over 2.75 million shares exchanged hands in the previous trading session. This number stood above the average volume of 3.96 million that was measured over a 30-day period.

Amarin Corporation plc (NASDAQ:AMRN) is a late-stage bio-pharma company. It specializes in lipid science that spotlights on the cardiovascular disease treatment.  AMR101, the Company’s product candidate is an ultra-pure omega 3 fatty acid. AMRN is developing AMR101 for the treatment of patients who suffer from hypertriglyceridemia or high triglyceride levels.  In September 2011, the company filed a New Drug Application, with the U. S Food and Drug Administration. It started patient dosing in its AMR101’s cardiovascular outcomes study in December 2011. The study is called REDUCE-IT (Reduction of Cardiovascular Events with eicosapentanoic acid.


About Michael Korte

Michael Korte an investigative reporter at GDP Insider and is a breaking news reporter. Michael work includes investigations of misconduct by federal prosecutors and industrial air pollution around the nation's schools. His reporting has been recognized with the Hillman Prize for Newspaper Journalism, the Grantham Prize for Excellence in Reporting on the Environment, and the Philip Meyer Journalism Award for reporting that incorporates social science methods.

View all post by Michael Korte Visit author's website

Write Your Comment